ALX 0141 for prevention of postmenopausal osteoporosis.

Trial Profile

ALX 0141 for prevention of postmenopausal osteoporosis.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2011

At a glance

  • Drugs ALX 0141 (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors Ablynx
  • Most Recent Events

    • 16 Nov 2011 Status changed from active, no longer recruiting to completed, according to an Ablynx media release.
    • 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 25 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism (EULAR-2011) (abstract OP-0198)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top